Diana DeGette actually said...

The goal of the biopharmaceutical accelerator will be in collaboration with our partners at NIAID.

The bacterium's resistance to colistin is particularly concerning because in this country physicians use colistin as the treatment of last r...

I wish you would, thanks, because maybe that can help illuminate--yes, Dr. Hatchett?

We have been worried for quite some time here in Congress and at the agencies about the risk of resistant antibiotics.